Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. (Q51151747)
Jump to navigation
Jump to search
scientific article published on 21 March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. |
scientific article published on 21 March 2014 |
Statements
1 reference
Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. (English)
1 reference
Atsushi Hirayama
1 reference
Narimon Honarpour
1 reference
Masayuki Yoshida
1 reference
Shizuya Yamashita
1 reference
Fannie Huang
1 reference
Scott M Wasserman
1 reference
Tamio Teramoto
1 reference
21 March 2014
1 reference
1 reference
78
1 reference
1073-1082
1 reference
5
1 reference
Identifiers
1 reference